Enrolling by invitationNot applicableNCT07405346

A Trial for Advanced Leiomyosarcoma With Human Organoid-guided Personalized Efficacy

Studying Leiomyosarcoma

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Intervention
treatment based on the results of drug sensitivity analysis(drug)
Enrollment
50 target
Eligibility
18-75 years · All sexes
Timeline
2026 – 2027

Study locations (1)

Collaborators

Fudan University · Zhejiang Cancer Hospital · West China Hospital · Xiangya Hospital of Central South University · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Peking University Cancer Hospital & Institute · Cancer Institute and Hospital, Chinese Academy of Medical Sciences · First Affiliated Hospital of Guangxi Medical University · Hubei Cancer Hospital · Henan Cancer Hospital · Second Xiangya Hospital of Central South University · Tianjin Hospital · First Affiliated Hospital of Fujian Medical University

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07405346 on ClinicalTrials.gov

Other trials for Leiomyosarcoma

Additional recruiting or active studies for the same condition.

See all trials for Leiomyosarcoma →

← Back to all trials